

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

[gov.uk/mhra](https://www.gov.uk/mhra)

Decision Cover Letter

Decision of the licensing authority to:

grant a product specific waiver

MHRA-101115-PIP01-23

Scope of the Application

Active Substance(s)

Sodium ((2S)-1,4-bis[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[2.2.2]octan-2-yl)oxy)methyl hydrogen phosphate-2-amino-2-(hydroxymethyl)propane-1,3-diol (1/1/1)

Condition(s)

Treatment of amyotrophic lateral sclerosis

Pharmaceutical Form(s)

Granules

Route(s) of Administration

ORAL USE

Name / Corporate name of the PIP applicant

Calico Life Sciences LLC

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Calico Life Sciences LLC submitted to the licensing authority on 23/09/2023 05:46 BST an application for a Paediatric Investigation Plan

The procedure started on 19/12/2023 15:04 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to grant a product specific waiver

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

[gov.uk/mhra](https://www.gov.uk/mhra)

Final Decision Letter

MHRA-101115-PIP01-23

Of 16/02/2024 17:48 GMT

On the adopted decision for Sodium ((2S)-1,4-bis[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[2.2.2]octan-2-yl}oxy)methyl hydrogen phosphate-2-amino-2-(hydroxymethyl)propane-1,3-diol (1/1/1) (MHRA-101115-PIP01-23) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Granting a waiver in all age groups for the listed condition(s)

This decision applies to a Paediatric Investigation Plan for Sodium ((2S)-1,4-bis[2-(4-chloro-3-fluorophenoxy)acetamido]bicyclo[2.2.2]octan-2-yl}oxy)methyl hydrogen phosphate-2-amino-2-(hydroxymethyl)propane-1,3-diol (1/1/1), Granules , ORAL USE .

This decision is addressed to Calico Life Sciences LLC, 1170 Veterans Blvd, South San Francisco, UNITED STATES OF AMERICA, 94080

ANNEX I

1. Waiver

1.1 Condition:

Treatment of amyotrophic lateral sclerosis The waiver applies / applied to: Paediatric Subset(s): All subsets of the paediatric population from birth to less than 18 years of age Pharmaceutical form(s): Granules Route(s) of administration: ORAL USE Reason for granting waiver: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible

2. Paediatric Investigation Plan:

2.1 Condition(s):

Not Applicable

2.2 Indication(s) targeted by the PIP:

Not Applicable

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

Not Applicable

2.4 Pharmaceutical Form(s):

Not Applicable

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	0	Not Applicable
Non-Clinical Studies	0	Not Applicable
Clinical Studies	0	Not Applicable
Extrapolation, Modeling & Simulation Studies	0	Not Applicable
Other Studies	0	Not Applicable
Other Measures	0	Not Applicable

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	
Date of completion of the paediatric investigation plan:	
Deferral of one or more studies contained in the paediatric investigation plan:	

